Proposed OTC Switch Rule Anticipates Digital World
Executive Summary
FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.
You may also be interested in...
‘Critical Step’ For Petros Toward ED Switch Proposal With OTC Label Comprehension Study
Firm reports “significant comprehension” among 480 participants. It also expects DFL technology it’s developing for potential OTC sales of Stendra ED drug could be used for other OTC switch proposals.
US Consumer Health Industry In 2023: Monograph Results, Switch Hopes On OTC Drug Sector Radar
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight reports on OTC drug sector’s outlook for the FDA potentially publishing a final rule to expand switch opportunities as well as its anticipation of marketplace results from monograph program overhaul.
Will ACNU Proposal’s Dual Rx/OTC Component Simultaneously Help And Hinder Switches?
Proposal is counter to fundamental of FDA platform for approving drugs as either Rx or OTC, with a formulation of a drug with a certain indication available in one class, not both. CHPA says the proposal also runs counter to encouraging pharma firms to invest in research needed for OTC switches.